Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

NCT07702292 is registered in ClinicalTrials.gov with Blue Earth Diagnostics as lead sponsor.

NCT NCT07702292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07702292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Lead sponsor
Blue Earth Diagnostics
Phase
Phase 2
Overall status
Recruiting
Start date
June 30, 2026
Completion date
February 29, 2028
Enrollment
71 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, epithelial ovarian cancer, gastric cancer (gc), invasive lobular breast carcinoma, pancreatic ductal adenocarcinoma (pdac)